<DOC>
	<DOC>NCT00141804</DOC>
	<brief_summary>To study the efficacy and safety of the administration of Tacrolimus in combination with Sirolimus for the prevention of acute rejection in patients after renal transplantation</brief_summary>
	<brief_title>Efficacy and Safety of Sirolimus in Combination With Tacrolimus</brief_title>
	<detailed_description>Basic randomized clinical trial (multicentre) in primary KTX to assess the safety and efficacy of a tac/rapa vs a tac/MMF regimen. Tac trough levels in accordance with current standards in both arms. Steroids to be used to individual centre protocol. Rapa trough levels will be adjusted to 5-10 ng/ml. Up to now only few data (primate and clinical) on tac/rap combinations available.</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>first kidney transplantation retransplantation nonrelated living donor transplantation patients &gt; 18 years patients have given their written consent after being informed female patients in the age of parity must consent to an effective birth control and submit a negative pregnancy test related living donation patients with known HIVanamnesis patients who need systemically administered immunosuppression for another indication than the prophylaxis of kidney graft rejection patients with present malignant disease patients with clinically significant, uncontrolled infectional disease and/or severe diarrhea, vomiting or active gastric ulcer patients who haven taken part in a clinical study in the past 28 days and/or receive (received) medication which is not licensed by the responsible health authority other reasons which depend on the assessment of the physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>renal transplantation</keyword>
	<keyword>immunosuppression</keyword>
	<keyword>prevention of acute rejection</keyword>
</DOC>